Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>The Chemours Company's latest financial performance and strategic direction are reflective of significant operational efforts, though tempered by challenges across various segments.</li><li>In the fourth quarter of 2024, Chemours reported consolidated net sales of approximately $1.4 billion, a slight 1% decrease compared to the prior year.</li><li>Concurrently, adjusted EBITDA rose modestly from $176 million to $179 million, indicating that cost-saving measures were effectively offsetting some declines in pricing and sales.</li></ul>

The Chemours Company's latest financial performance and strategic direction are reflective of significant operational efforts, though tempered by challenges across various segments.In the fourth quarter of 2024, Chemours reported consolidated net sales of approximately $1.4 billion, a slight 1% decrease compared to the prior year.Concurrently, adjusted EBITDA rose modestly from $176 million to $179 million, indicating that cost-saving measures were effectively offsetting some declines in pricing and sales.

Chemours Company: These Are The 5 Biggest Challenges In Its Path!

External reports (aggregated public sources), Value Investors Club

Value Investors Club (VIC)

External reports (aggregated public sources)

Value Investors Club

<ul><li>Chemours is a chemical producer with a diverse portfolio in three segments</li><li>Stock value decline due to poor TiO2 trends and weak refrigerant performance</li><li>Expected earnings improvement in the second half of the year driven by growth in refrigerants, duopoly in next generation refrigerants, and long-term growth potential in data center cooling technology</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

Chemours is a chemical producer with a diverse portfolio in three segmentsStock value decline due to poor TiO2 trends and weak refrigerant performanceExpected earnings improvement in the second half of the year driven by growth in refrigerants, duopoly in next generation refrigerants, and long-term growth potential in data center cooling technologyThis content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Chemours Co (CC) - Thursday, Sep 26, 2024

<ul><li>The Chemours Company’s third-quarter 2024 results present a mixed picture, reflecting both commendable strategic implementation and ongoing market challenges.</li><li>The quarter witnessed a 1% increase in consolidated net sales to approximately $1.5 billion, driven by a 5% rise in volume, though partially offset by a 3% decline in pricing and a slight currency headwind.</li><li>This reflects the company's effective operational execution and successful navigation through previous disruptions, evidenced by year-over-year volume growth across all business segments.</li></ul>

The Chemours Company’s third-quarter 2024 results present a mixed picture, reflecting both commendable strategic implementation and ongoing market challenges.The quarter witnessed a 1% increase in consolidated net sales to approximately $1.5 billion, driven by a 5% rise in volume, though partially offset by a 3% decline in pricing and a slight currency headwind.This reflects the company's effective operational execution and successful navigation through previous disruptions, evidenced by year-over-year volume growth across all business segments.

The Chemours Company: Its’ Strategic Portfolio Overhaul Maximizing Returns in High-Growth Markets! - Major Drivers

<ul><li>The Chemours Company faced various challenges in the second quarter of 2024, yet demonstrated resilience and adaptability in managing these issues.</li><li>Key points from the earnings call include the impact of a severe drought on their titanium dioxide production at Altamira, Mexico, which led to unplanned downtime and an $8 million cost for the quarter.</li><li>Despite this, Chemours was proactive in addressing the immediate needs of affected employees and the community while optimizing production to meet customer demands, achieving a 16% increase in volumes compared to the first quarter.</li></ul>

The Chemours Company faced various challenges in the second quarter of 2024, yet demonstrated resilience and adaptability in managing these issues.Key points from the earnings call include the impact of a severe drought on their titanium dioxide production at Altamira, Mexico, which led to unplanned downtime and an $8 million cost for the quarter.Despite this, Chemours was proactive in addressing the immediate needs of affected employees and the community while optimizing production to meet customer demands, achieving a 16% increase in volumes compared to the first quarter.

The Chemours Company: Expansion of Fluoropolymer Applications & Dealing With Fluctuating Demand! - Major Drivers

<ul><li>The Chemours Company's fourth quarter and year-end 2023 earnings revealed a mixed bag of results, reflecting both the challenges and potential for the company.</li><li>On one side, the company faced various hurdles including softness in economically sensitive end markets, higher input costs, and extended outage at one of the manufacturing sites.</li><li>Despite these headwinds, Chemours still demonstrated strong areas of growth and several promising developments, emphasizing the resilience and potential the company has.</li></ul>

The Chemours Company's fourth quarter and year-end 2023 earnings revealed a mixed bag of results, reflecting both the challenges and potential for the company.On one side, the company faced various hurdles including softness in economically sensitive end markets, higher input costs, and extended outage at one of the manufacturing sites.Despite these headwinds, Chemours still demonstrated strong areas of growth and several promising developments, emphasizing the resilience and potential the company has.

The Chemours Company: What Are The Potential Growth Opportunities Ahead? - Major Drivers

United States

The Chemours Company manufactures and distributes performance chemicals. The Company produces titanium dioxide, refrigerants and industrial fluoropolymer resins, and industrial and specialty chemicals for gold producing, oil refining, agriculture, and other industries.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Chemours Co/The (CC US)

Chemours Company: These Are The 5 Biggest Challenges In Its Path!

The Chemours Company's latest financial performance and strategic direction are reflective of significant operational efforts, though tempered by...

Baptista Research

Chemours Co (CC) - Thursday, Sep 26, 2024

Chemours is a chemical producer with a diverse portfolio in three segments. Stock value decline due to poor TiO2 trends and weak refrigerant...

Value Investors Club (VIC)

The Chemours Company: Its’ Strategic Portfolio Overhaul Maximizing Returns in High-Growth Markets! - Major Drivers

The Chemours Company’s third-quarter 2024 results present a mixed picture, reflecting both commendable strategic implementation and ongoing market...

Baptista Research

The Chemours Company: Expansion of Fluoropolymer Applications & Dealing With Fluctuating Demand! - Major Drivers

The Chemours Company faced various challenges in the second quarter of 2024, yet demonstrated resilience and adaptability in managing these...

Baptista Research

The Chemours Company: What Are The Potential Growth Opportunities Ahead? - Major Drivers

The Chemours Company's fourth quarter and year-end 2023 earnings revealed a mixed bag of results, reflecting both the challenges and potential for...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)